Michael R Ardern-Jones
Overview
Explore the profile of Michael R Ardern-Jones including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
39
Citations
608
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Todorov A, Goyal K, Torah R, Greig T, Ardern-Jones M, Beeby S
Annu Int Conf IEEE Eng Med Biol Soc
. 2025 Mar;
2024:1-4.
PMID: 40039506
Atopic dermatitis is the most common inflammatory skin disease worldwide but empirical work on monitoring the condition using digital technologies is lacking. This work presents a skin model for predicting...
2.
Ardern-Jones M, Brown S, Flohr C, Hossain P, Irvine A, Johnston G, et al.
Br J Dermatol
. 2024 Sep;
191(6):865-885.
PMID: 39236226
Atopic dermatitis (AD) is the most common inflammatory skin condition and affects people of all ages. New therapies, including the monoclonal antibody therapy dupilumab, offer excellent efficacy. However, in clinical...
3.
Alexander H, Malek R, Prieto-Merino D, Gribaleva E, Baden M, Beattie P, et al.
Br J Dermatol
. 2024 Jul;
191(6):988-999.
PMID: 39044673
Background: The main conventional systemic treatments for atopic dermatitis (AD) are methotrexate (MTX) and ciclosporin (CyA). Dupilumab was the first novel systemic agent to enter routine clinical practice. There are...
4.
Todorov A, Torah R, Wagih M, Ardern-Jones M, Beeby S
Sensors (Basel)
. 2023 Dec;
23(24).
PMID: 38139759
**Mahmoud Wagih** was not included as an author in the original publication [...].
5.
Warren R, Basey V, Lynam A, Curtis C, Ardern-Jones M
Br J Dermatol
. 2023 Jul;
189(4):427-436.
PMID: 37418627
Background: Atopic dermatitis (AD) is a common chronic inflammatory skin condition. While other chronic inflammatory conditions are associated with increased risk of venous thromboembolism (VTE), associations between AD and VTE...
6.
Sirvent S, Vallejo A, Corden E, Teo Y, Davies J, Clayton K, et al.
Nat Commun
. 2023 May;
14(1):2880.
PMID: 37208336
Regulation of cutaneous immunity is severely compromised in inflammatory skin disease. To investigate the molecular crosstalk underpinning tolerance versus inflammation in atopic dermatitis, we utilise a human in vivo allergen...
7.
Todorov A, Torah R, Wagih M, Ardern-Jones M, Beeby S
Sensors (Basel)
. 2023 Apr;
23(8).
PMID: 37112275
Atopic dermatitis (AD) is one of the most common skin disorders, affecting nearly one-fifth of children and adolescents worldwide, and currently, the only method of monitoring the condition is through...
8.
Flohr C, Cork M, Ardern-Jones M, Eichenfield L, Barbarot S, Feeney C, et al.
J Dermatolog Treat
. 2023 Apr;
34(1):2200866.
PMID: 37036183
Background: Differences in atopic dermatitis (AD) disease course and manifestation with age may extend to treatment response. Objective: To evaluate response maintenance with continuous-/reduced-dose abrocitinib or withdrawal and response to...
9.
Ardern-Jones M, Buchanan E, Njungu S, ODriscoll D
Br J Dermatol
. 2023 Jan;
188(5):678-679.
PMID: 36662536
No abstract available.
10.
Ardern-Jones M, Phan H, Borca F, Stammers M, Batchelor J, Reading I, et al.
PLoS One
. 2023 Jan;
18(1):e0280079.
PMID: 36649371
Background: The success of early dexamethasone therapy for hospitalised COVID-19 cases in treatment of Sars-CoV-2 infection may predominantly reflect its anti-inflammatory action against a hyperinflammation (HI) response. It is likely...